NEUP Stock Summary and Trading Ideas (Neuphoria Therapeutics | NASDAQ:NEUP)

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Neuphoria Therapeutics trades on the NASDAQ stock market under the symbol NEUP.

As of February 5, 2026, NEUP stock price declined to $3.98 with 23,831 million shares trading.

NEUP has a beta of -0.41, meaning it tends to be less sensitive to market movements. NEUP has a correlation of 0.00 to the broad based SPY ETF.

NEUP has a market cap of $21.40 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that NEUP belongs to (by Net Assets): PSIL, VXF.

NEUP has underperformed the market in the last year with a price return of -21.8% while the SPY ETF gained +14.0%. NEUP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.7% and -1.5%, respectively, while the SPY returned +0.8% and -1.0%, respectively.

NEUP support price is $3.84 and resistance is $4.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEUP shares will trade within this expected range on the day.